## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.2% in lower entry zone (4.0-10.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (0.6%) confirms momentum alignment. Outperforming sector by 8.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($79.95)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. HSBC Adjusts Price Target on GE Healthcare Technologies to $100 From $87, Maintains Buy Rating**
- Source: marketscreener.com | 20251208T130814 | Bullish | Relevance: 99%
-  HSBC has raised its price target for GE Healthcare Technologies (GEHC) from $87 to $100, while reiterating a "Buy" rating on the stock. This adjustment comes amidst ongoing news about GE HealthCare's strategic developments, including new partnerships and technological advancements in medical imaging and diagnostics. The company continues to declare quarterly dividends and introduces advanced solutions powered by AI and NVIDIA technology.

**2. Sant' Andrea University Hospital to Integrate GE HealthCare and Tribun Health's Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care**
- Source: Fox 59 | 20251210T141029 | Bullish | Relevance: 99%
-  Sant' Andrea University Hospital is integrating GE HealthCare's Enterprise Imaging platform and Tribun Health's CaloPixÂ® digital pathology solution to unify radiology and pathology. This collaboration aims to create a seamless, AI-ready environment for data-driven cancer care, accelerating diagnostics, and improving patient outcomes. The investment, partially funded by the National Recovery and Resilience Plan, positions Sant' Andrea at the forefront of digital pathology in Lazio.

**3. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: Business Wire | 20251209T150810 | Bullish | Relevance: 99%
- The AI-Powered Medical Devices Market is projected to reach $59.8 billion by 2032, growing at an 18.26% CAGR from $18.36 billion in 2025. This growth is driven by technological advancements, increasing adoption in clinical settings, and supportive reimbursement frameworks. Key players include GE HealthCare, Siemens Healthineers, and Philips, with AI integrating across all stages of device lifecycle to enhance diagnostics, monitoring, and treatment.

**4. GE HealthCare, Mayo Clinic expand partnership around radiology research**
- Source: MedTech Dive | 20251209T161709 | Bullish | Relevance: 98%
-  GE HealthCare and Mayo Clinic have expanded their partnership, called GEMINI-RT, to personalize radiation therapy and cancer care through the integration of imaging, AI, and patient monitoring. The collaboration aims to move away from a "one-size-fits-all" approach by optimizing radiation doses based on individual patient data and monitoring for early side effects. This five-year initiative will explore clinical trials and integrate innovations into GE HealthCare's product portfolio globally.

**5. These Healthcare Stocks Have Bullish Charts: GE Healthcare, STERIS, and Hinge Health**
- Source: Barron's | 20251209T170812 | Bullish | Relevance: 98%
- Several non-biotech healthcare stocks like GE Healthcare, STERIS, and Hinge Health are demonstrating strong momentum with bullish charts, breaking out of bases, and showing accelerating relative strength. These medical technology, services, and equipment stocks are becoming sector leaders, indicating potential for continued standout performance. Investors are rotating towards these names due to their sustained upside follow-through and clean technical setups.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 17.1x stretched relative to 9% growth. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 17.1 |
| Current P/E | 18.6 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 81st percentile. MRS_5 at 0.6% confirms short-term momentum alignment. AM_20 at 7.8% shows strong absolute momentum above own 20MA. Outperforming sector by 8.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.64), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.23% (CS: 81) | Strong |
| RSI_14 | 65.6 | Neutral |
| MACD Histogram | 0.64 | Bullish |
| vs SMA20 | 1.078x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.132x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $84.47
- **Stop Loss:** $79.95 (5.4% risk)
- **Target:** $91.25 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 110
- **Position Value:** $9,291.70
- **Portfolio %:** 9.29%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*